References
1. Coronavirus disease (COVID-19) Situation Report– 106. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505covid-19-sitrep-106.pdf?sfvrsn=47090f63_2. Accessed 14th May 2020
2. DerSimonian R, Laird N. Meta-analysis in clinical trials.Control Clin Trials. 1986;7(3):177-188.
3. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
4. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ. 2011;343:d5928.
5. Bessiere F, Roccia H, Deliniere A, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.JAMA Cardiol 2020 [E-pub ahead of print] https://dx.doi.org/10.1001/ jamacardio.2020.1787.
6. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 [E-pub ahead of print], https://dx.doi.org/10.1001/jamacardio.2020.1834.
7. Saleh M, Gabriels J, Chang D, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol.2020. [E-pub ahead of print], https://dx.doi.org/10.1161/ CIRCEP.120.008662.
8. Chang D, Saleh M, Gabriels J, et al. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin. J Am Coll Cardiol. 2020 . [E-pub ahead of print], https://dx.doi.org/10.1016/j.jacc.2020.04.032.